Abstract
Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism, is a cause of significant mortality and morbidity. For several decades, anticoagulant options for the treatment and prevention of thrombosis have been limited mainly to agents such as unfractionated heparin and oral vitamin K antagonists such as warfarin. Although these therapies have proven benefits, they also have important limitations that result in their underuse in routine clinical practice. A variety of novel anticoagulants with improved pharmacologic and clinical profiles are in development, offering benefits over traditional therapies. Specifically, progress has been made in the development of small molecule Factor Xa inhibitors and thrombin inhibitors. The most advanced drugs reviewed include DPC-423, DPC- 602, razaxaban, GSKs 813893, Portolas Xa inhibitors (formerly Millennium), otamixaban, DU-176b, KFA-1982, BAY- 59-7939, DX-9065a, YM-150, LY-517717, Exanta, 3DPs thrombin inhibitors, SSR-182289, LB-30057, LB-30870, BIBR-1048 and Mercks thrombin inhibitors. With their potentially consistent and predictable pharmacological profile, oral formulation, and decreased need for coagulation monitoring, these new agents will likely increase the use and duration of anticoagulation treatment in thromboembolic disorders and reduce the burden associated with long-term management.
Keywords: Venous thromboembolism, Anticoagulant Agent, DPC-423, Razaxaban, antithrombotic, LY-517717
Current Topics in Medicinal Chemistry
Title: Small Molecule Coagulation Cascade Inhibitors in the Clinic
Volume: 5 Issue: 16
Author(s): Eddine Saiah and Chris Soares
Affiliation:
Keywords: Venous thromboembolism, Anticoagulant Agent, DPC-423, Razaxaban, antithrombotic, LY-517717
Abstract: Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism, is a cause of significant mortality and morbidity. For several decades, anticoagulant options for the treatment and prevention of thrombosis have been limited mainly to agents such as unfractionated heparin and oral vitamin K antagonists such as warfarin. Although these therapies have proven benefits, they also have important limitations that result in their underuse in routine clinical practice. A variety of novel anticoagulants with improved pharmacologic and clinical profiles are in development, offering benefits over traditional therapies. Specifically, progress has been made in the development of small molecule Factor Xa inhibitors and thrombin inhibitors. The most advanced drugs reviewed include DPC-423, DPC- 602, razaxaban, GSKs 813893, Portolas Xa inhibitors (formerly Millennium), otamixaban, DU-176b, KFA-1982, BAY- 59-7939, DX-9065a, YM-150, LY-517717, Exanta, 3DPs thrombin inhibitors, SSR-182289, LB-30057, LB-30870, BIBR-1048 and Mercks thrombin inhibitors. With their potentially consistent and predictable pharmacological profile, oral formulation, and decreased need for coagulation monitoring, these new agents will likely increase the use and duration of anticoagulation treatment in thromboembolic disorders and reduce the burden associated with long-term management.
Export Options
About this article
Cite this article as:
Saiah Eddine and Soares Chris, Small Molecule Coagulation Cascade Inhibitors in the Clinic, Current Topics in Medicinal Chemistry 2005; 5 (16) . https://dx.doi.org/10.2174/156802605775009702
DOI https://dx.doi.org/10.2174/156802605775009702 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Early Postoperative Bleeding in Polytrauma Patients Treated with Fondaparinux: Literature Review and Institutional Experience
Current Vascular Pharmacology High Sensitivity Troponin in Cardiovascular Disease. Is There More Than a Marker of Myocardial Death?
Current Topics in Medicinal Chemistry Management of the Menopausal Disturbances and Oxidative Stress
Current Pharmaceutical Design Emerging Therapy Options in Heparin-Induced Thrombocytopenia
Cardiovascular & Hematological Agents in Medicinal Chemistry Endovascular Treatment of Pulmonary and Cerebral Arteriovenous Malformations in Patients Affected by Hereditary Haemorrhagic Teleangiectasia
Current Pharmaceutical Design Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Misoprostol-induced Acute Coronary Syndrome in a Premenopausal Woman: A Case Report with Literature Review
Current Drug Safety Pharmacogenetically Tailored Treatments for Heart Disease
Current Pharmaceutical Design Behavioral Effects of 2,3-Dihydro- and Oxoisoaporphine Derivatives in Post Stroke-Depressive Like Behavior in Male Balb/c Mice
Current Topics in Medicinal Chemistry First Comprehensive Analysis of Outcomes in Adult Patients after Percutaneous Closure of Isolated Secundum Atrial Septal Defects
Cardiovascular & Hematological Agents in Medicinal Chemistry Risk-Benefit Perspectives in COX-2 Blockade
Current Drug Safety Thrombophilia in Pregnancy: Maternal and Fetal Implications
Current Women`s Health Reviews Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?
Cardiovascular & Hematological Agents in Medicinal Chemistry Acute Phase Treatment of Pulmonary Embolism
Current Vascular Pharmacology Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology New Oral Anticoagulation after Heart Valve Replacement
Cardiovascular & Hematological Disorders-Drug Targets Clopidogrel and Aspirin in Cardiovascular Medicine: Responders or Not -- Current Best Available Evidence
Cardiovascular & Hematological Agents in Medicinal Chemistry Hemolysis-Associated Pulmonary Hypertension in Sickle Cell Disease: Global Disruption of the Arginine-Nitric Oxide Pathway
Current Hypertension Reviews Nano-Systems for Advanced Therapeutics and Diagnosis of Atherosclerosis
Current Pharmaceutical Design MMP-9 Inhibitors in the Brain: Can Old Bullets Shoot New Targets?
Current Pharmaceutical Design